Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

February 12, 2025

Study Completion Date

February 12, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

RP-6306 (oral PKMYT1 inhibitor)

RP-6306 (Oral) in combination with FOLFIRI (IV)

Trial Locations (9)

10032

#1008, Columbia University, New York

33612

#1022, Moffitt Cancer Center, Tampa

77030

#1001, The University of Texas M.D. Anderson Cancer Center, Houston

84112

#1013, The University of Utah, Huntsman Cancer Center, Salt Lake City

90095

#1019, UCLA, Westwood Cancer Center, Los Angeles

ON M5G 2M9

# 2001, Princess Margaret Cancer Centre, Toronto

Unknown

# 5002, South Texas Accelerated Research Therapeutics, Madrid

# 5003, Hospital Universitario HM Sanchinarro, Madrid

W1G 6AD

# 3003, Sarah Cannon Research Institute, London

Sponsors
All Listed Sponsors
lead

Repare Therapeutics

INDUSTRY

NCT05147350 - Study of RP-6306 With FOLFIRI in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter